BDSX News and Press, Biodesix Inc. From 03/03/25

2025-03-03 16:06:30 ET More on Biodesix Seeking Alpha’s Quant Rating on Biodesix Historical earnings data for Biodesix Financial information for Biodesix Read the full article on Seeking Alpha For further details see: Biodesix GAAP EPS of -...

Total Revenue of $71.3 million for FY2024, growing 45% over FY2023; Gross margins of 78% for FY2024, up 5% points over FY2023 ; FY2025 Total Revenue Guidance of $92-95 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., March 03, 2025 (G...

BBB Foods Inc. Class A (TBBB) is expected to report $0.02 for Q4 2024 Beamr Imaging Ltd. (BMR) is expected to report for quarter end 2024-12-31 Transportadora de Gas del Sur SA TGS (TGS) is expected to report $0.5 for Q4 2024 Henkel AG & Co. KGAA ADR (HENKY) is expected to report ...

BOULDER, Colo., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at...

BOULDER, Colo., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2024 after the close of trading on Monday, March 3. Biodesix manag...

2025-01-10 06:22:35 ET More on Biodesix Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Biodesix Historical earnings data for Biodesix Financial information for Biodesix Read the full article on Seeking ...

LOUISVILLE, Colo., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2024 (fiscal 2024). The financial results included in this release perta...

LOUISVILLE, Colo., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, announced a new post-market clinical validation study was published in CHEST Pulmonary Journal that reaffirms the previously establi...